#United States #New York #Class Action #Levi Korsinsky #Neumora Therapeutics

Levi & Korsinsky Notifies Investors of Class Action Lawsuit Against Neumora Therapeutics

In a recent announcement, Levi & Korsinsky, LLP, a law firm known for advocating for investor rights, has alerted shareholders of Neumora Therapeutics, Inc. about a pending class action lawsuit concerning potential securities fraud. This initiative is directed towards all the individuals who purchased Neumora's common stock linked to its Offering Documents, with the purchase period starting around September 15, 2023. If you are affected by these circumstances, now is the time to act, as deadlines are approaching.

Details of the Class Action

The class action has emerged in light of allegations indicating that Neumora Therapeutics engaged in misleading practices that had a significant adverse impact on its investors. The lawsuit specifically claims that the defendants made false declarations, particularly regarding the expectations and requirements of their Phase Three clinical trials.

According to the filed complaint, it is asserted that:
1. To proceed with its Phase Three Program, Neumora was compelled to modify the original inclusion criteria from BlackThorn's Phase Two trial, adding participants with moderate to severe Major Depressive Disorder (MDD). This adjustment was believed necessary to validate the statistical significance of Navacaprant intended to treat MDD.
2. The Company also introduced a prespecified analysis focused on patients with moderate to severe MDD within the Phase Two statistical analysis plan, aiming to strengthen its claims about the therapeutic effectiveness of their candidate.
3. Furthermore, it was suggested that the Phase Two Trials lacked sufficiently robust data, notably regarding patient demographics, which should have been adequate to anticipate outcomes in the subsequent KOASTAL-1 study.

Submission Process for Affected Investors

Investors who experienced financial losses during the specified timeframe are urged to act before the critical deadline of April 7, 2025, which is the date to request the Court to appoint them as lead plaintiffs. However, it is important to note that participating in the compensation recovery does not necessitate taking up the lead plaintiff position.

No Financial Burden for Class Members

A significant aspect of the class action initiative is that investors may be eligible for financial compensation without incurring any out-of-pocket costs. The firm emphasizes that there are no fees or obligations for those who wish to partake in the proceedings, making this an accessible avenue for investors seeking redress.

Levi & Korsinsky: A History of Success

Levi & Korsinsky has established a formidable reputation over the last two decades, successfully recovering hundreds of millions of dollars for aggrieved shareholders. The firm's proficiency in handling complex securities litigation cases garners it a place among the top securities litigation firms in the United States, as evidenced by consistent inclusion in ISS Securities Class Action Services' prestigious Top 50 Report.

Contact Information for Concerned Investors

For individuals interested in learning more about this case or participation, Levi & Korsinsky invites inquiries via email at info@zlk.com or by telephoning their offices directly at (212) 363-7500. Providing transparency and support, the legal team is ready to assist those affected in navigating through this challenging situation.

As the deadline approaches, it is imperative for investors of Neumora Therapeutics to stay informed and take the necessary steps to protect their financial interests against the backdrop of this unfolding legal situation.

For more detailed information and to get in touch with their team, visit Levi & Korsinsky's official website.